FDA gives Novartis’ Ilaris big boost with nod for rare juvenile diabetes

Eric Palmer

has grabbed one of two new indications it was shooting for with its disease drug , one step toward turning the drug into a blockbuster.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS